Published: Sat, May 13, 2017
Markets | By Noel Gibbs

Short Interest in Sangamo Therapeutics Inc (SGMO) Increases By 2.0%

Short Interest in Sangamo Therapeutics Inc (SGMO) Increases By 2.0%

Zacks Investment Research cut shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) from a hold rating to a sell rating in a report published on Wednesday.

The deal centers around Sangamo's lead gene therapy candidate SB-525, which it hopes to eventually offer as a one-time treatment for hemophilia A.

SB-525 works as a AAV vector carrying a Factor VIII gene construct driven by a synthetic, liver-specific promoter.

Sangamo's gene therapies are based on its multi-platform technology, including its zinc finger nuclease (ZFN) knock-out gene tool, and both adeno associated virus (AAV) and messenger RNA delivery tech.

Judge orders criminal charges against Amtrak 188 engineer
It's rare but not unprecedented for citizens to seek private criminal complaints when they object to a prosecutor's decision. Epstein says state Attorney General Josh Shapiro could also negotiate a plea or take time to evaluate the case.

SGMO has been the topic of several research analyst reports. Analysts had estimated a loss of 28 cents a share on revenue of $4 million.

08/08/2016 - Sangamo BioSciences, Inc. had its "buy" rating reiterated by analysts at Cowen. Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday, March 1st. A rating of 1 or 2 would represent a Buy, and a 3 rating would signify a Hold on the stock.

12/03/2015 - Wells Fargo began new coverage on Sangamo BioSciences, Inc. giving the company a " rating. Sangamo Therapeutics, Inc. (NASDAQ:SGMO)'s 12 month volatility is presently 80.579700. The company's market capitalization is $455.97 million with the total outstanding shares of 71.78 million. The firm has a 50 day moving average of $4.45 and a 200-day moving average of $3.89. The stock stands almost $3.3 off versus the 52-week high of $7.6 and $1.65 above the 52-week low of $2.65.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, February 28th. Analysts are forecasting earnings of $-0.29 on a per share basis this quarter. Sangamo Therapeutics had a negative return on equity of 45.02% and a negative net margin of 388.23%. The business had revenue of $3.40 million for the quarter, compared to the consensus estimate of $4.14 million. Sangamo shares jumped 42% to $6.15 after hours.

Google Maps uses Street View to keep you on the right path
And normally too, when we travel to some unknown place the best friend we have in our hand is Google Maps. The news of this "ready" hardware is being announced this week during a Street View Summit in Tokyo.

ILLEGAL ACTIVITY WARNING: This story was reported by [[site]] and is the sole property of of [[site]]. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and worldwide copyright law. The original version of this story can be viewed at [[permalink]].

In recent action, Sangamo Therapeutics, Inc. NY boosted its stake in shares of Sangamo Therapeutics by 1.6% in the fourth quarter. Tocqueville Asset Management L.P. boosted its stake in Sangamo Therapeutics by 57.8% in the first quarter. NY now owns 49,713 shares of the biopharmaceutical company's stock worth $152,000 after buying an additional 780 shares during the period. The score is named after its developer Joseph Piotroski who created a ranking scale from 0-9 to help determine the financial strength of a company. Institutional investors and hedge funds own 61.87% of the company's stock. Finally, Altrinsic Global Advisors LLC increased its position in Sangamo Therapeutics by 26.0% in the third quarter.

Penumbra Inc (NYSE:PEN) shares ended at $89.45 with 0.83 mln shares exchanging hands.

About Sangamo Therapeutics Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company.

Wells Fargo announces US$2b in additional cost cuts
The current share price indicate that stock is -11.61% away from its one year high and is moving 13.89% ahead of its 52-week low. Becker Capital Management Inc increased Wells Fargo & Co New Com (WFC) stake by 14.06% reported in 2016Q4 SEC filing.

Like this: